Tygacil

RSS

tigecycline

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Tygacil. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tygacil.

This EPAR was last updated on 01/10/2019

Authorisation details

Product details
Name
Tygacil
Agency product number
EMEA/H/C/000644
Active substance
Tigecycline
International non-proprietary name (INN) or common name
tigecycline
Therapeutic area (MeSH)
  • Bacterial Infections
  • Skin Diseases, Bacterial
  • Soft Tissue Infections
Anatomical therapeutic chemical (ATC) code
J01AA12
Publication details
Marketing-authorisation holder
Pfizer Europe MA EEIG
Revision
29
Date of issue of marketing authorisation valid throughout the European Union
24/04/2006
Contact address

Boulevard de la Plaine 17
1050 Bruxelles
Belgium

Product information

09/04/2019 Tygacil - EMEA/H/C/000644 - N/0108

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antibacterials for systemic use

Therapeutic indication

Tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections:

  • Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections
  • Complicated intra-abdominal infections (cIAI)

Tygacil should be used only in situations where other alternative antibiotics are not suitable.

Consideration should be given to official guidance on the appropriate use of antibacterial agents. appropriate use of antibacterial agents.

Assessment history

How useful was this page?

Add your rating